medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 5

<< Back

Ann Hepatol 2012; 11 (5)

Silybin/Silymarin treatment in chronic hepatitis C

Barbero-Becerra VJ, Méndez-Sánchez N

Language: English
References: 14
Page: 731-733
PDF size: 69.64 Kb.


Text Extraction

Comments
Chronic HCV infection leads to cirrhosis and hepatocellular carcinoma and causes more than 300,000 deaths per year. Current treatment is based on a combination of pegylated interferon (Peg-IFN) and ribavirin in combination with oral protease inhibitors of HCV like boceprevir and telaprevir, which directly inhibits HCV replication and drives progressive infected cell clearance through intricate and only partly understood mechanisms. Multidrug resistance represents an increasing problem in the treatment of several diseases. It often appears after prolonged exposure of cells to a single drug and is characterized by cells resistance to structurally unrelated compounds. It has been demonstrated that current therapy could eradicate just certain HCV genotypes. In addition, certain limitations associated with current treatment as side effects and poor response leads to the need to search better anti-HCV therapies.


REFERENCES

  1. Brashier DB, Sharma S, Mathur AG, Khare P, Gupta S. Boceprevir: A new hope against hepatitis C virus. J Pharmacol Pharmacother 2012; 3: 213-5.

  2. Hofmann WP, Sarrazin C, Zeuzem S. Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int 2012; 109: 352-8.

  3. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, Pohl RT, Pawlotsky JM. Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. Gastroenterology 2010; 138: 1112-22.

  4. Gažák R, Walterová D, Kren V. Silybin and Silymarin-New and Emerging Applications in Medicine. Curr Med Chem 2007; 14: 315-38.

  5. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004; 36: 57-104.

  6. Polyak SJ, Morishima C, Shuhart MC, et al. Inhibition of Tcell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized silymarin. Gastroenterology 2007; 132: 1925-36.

  7. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 1561-7.

  8. Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, Owen DM, et al. Multiple Effects of Silymarin on the Hepatitis C Virus Lifecycle. Hepatology 2010; 51: 1912-21.

  9. Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS. Understanding silibinin’s modes of action against HCV using viral kinetic modeling. J Hepatol 2012; 56: 1019-24.

  10. Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy. A randomized controlled trial. JAMA 2012; 308: 274-282.

  11. Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy R, Wahed AS, et al. Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C. J Clin Pharmacol 2010; 50: 434-49.

  12. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 2005; 12: 559-67.

  13. Ding T, Tian S, Zhang Z, Gu D, Chen Y, Shi Y, Sun Z. Determination of active component in silymarin by RP-LC and LC/MS. J Pharm Biomed Anal 2001; 26: 155-61.

  14. Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pécheur EI, Tavis JE, Polyak SJ. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One 2011; 6: e16464.




2020     |     www.medigraphic.com